metformin has been researched along with Osteoporosis in 29 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate the effects of pioglitazone or metformin on bone mass and atherosclerosis in patients with type 2 diabetes." | 9.14 | Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. ( Kanazawa, I; Kurioka, S; Sugimoto, T; Yamaguchi, T; Yamamoto, M; Yamauchi, M; Yano, S, 2010) |
| "Metformin (MET) is widely used as a first-line hypoglycemic agent for the treatment of type 2 diabetes mellitus (T2DM) and was also confirmed to have a therapeutic effect on type 2 diabetic osteoporosis (T2DOP)." | 8.31 | Metformin suppresses Oxidative Stress induced by High Glucose via Activation of the Nrf2/HO-1 Signaling Pathway in Type 2 Diabetic Osteoporosis. ( Chen, B; Chen, C; Chen, P; Chen, W; Chi, W; He, Q; Li, M; Li, S; Pan, Z; Pang, X; Tu, H; Wang, F; Wang, H; Xiao, J; Yang, J; Yi, Y; Zeng, J, 2023) |
| "Metformin can prevent hyperglycaemia-induced osteoporosis and decrease the bone fracture rate, but the mechanism has not been fully elucidated." | 8.31 | Metformin promotes osteogenic differentiation and prevents hyperglycaemia-induced osteoporosis by suppressing PPARγ expression. ( Lian, H; Shen, X; Wang, S; Xie, Y; Yan, S; Zheng, L, 2023) |
| "To investigate the causal relationship between metformin use and osteoporosis and different subtypes of osteoporosis using a 2-sample Mendelian randomization method." | 8.31 | Causal association of metformin and osteoporosis: A 2-sample Mendelian randomization study. ( Chen, PB; Deng, GH; Ju, LL; Wei, YK, 2023) |
| "Linagliptin and its combination with metformin successfully ameliorated diabetic osteoporosis in HFD-fed mice possibly through modulation of BMP-2 and sclerostin." | 8.12 | Linagliptin in Combination With Metformin Ameliorates Diabetic Osteoporosis Through Modulating BMP-2 and Sclerostin in the High-Fat Diet Fed C57BL/6 Mice. ( Nirwan, N; Vohora, D, 2022) |
| "To investigate the metformin effect on the risk of osteoporosis (OS) and/or vertebral fracture (VF)." | 8.02 | Metformin use is associated with a lower risk of osteoporosis/vertebral fracture in Taiwanese patients with type 2 diabetes mellitus. ( Tseng, CH, 2021) |
| "Metformin may decrease cell senescence, including bone; hence we aimed at evaluating the association between metformin use and osteoporosis." | 7.96 | Metformin use is associated with a lower risk of osteoporosis in adult women independent of type 2 diabetes mellitus and obesity. REDLINC IX study. ( Aedo, S; Arriola-Montenegro, J; Arteaga, E; Belardo, A; Blümel, JE; Chedraui, P; Fighera, TM; López, M; Martino, M; Miranda, C; Miranda, O; Mostajo, D; Ñañez, M; Ojeda, E; Pilnik, S; Rojas, J; Salinas, C; Sosa, L; Spritzer, PM; Tserotas, K; Vallejo, MS, 2020) |
| "This study evaluated the preventative effects of metformin (Met) on glucocorticoid (GC)-induced osteoporosis in a rat model, compared with alendronate (Aln)." | 7.91 | Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats. ( Li, Q; Li, Y; Meng, Y; Shi, D; Zhang, H; Zhao, J; Zuo, L, 2019) |
| "Met may also treat diabetic osteoporosis through Wnt/β-catenin activation." | 5.72 | Metformin activates Wnt/β-catenin for the treatment of diabetic osteoporosis. ( Huang, X; Li, S; Lu, W; Xiong, L, 2022) |
| "The aim of this study was to investigate the effects of pioglitazone or metformin on bone mass and atherosclerosis in patients with type 2 diabetes." | 5.14 | Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. ( Kanazawa, I; Kurioka, S; Sugimoto, T; Yamaguchi, T; Yamamoto, M; Yamauchi, M; Yano, S, 2010) |
| "Metformin (MET) is widely used as a first-line hypoglycemic agent for the treatment of type 2 diabetes mellitus (T2DM) and was also confirmed to have a therapeutic effect on type 2 diabetic osteoporosis (T2DOP)." | 4.31 | Metformin suppresses Oxidative Stress induced by High Glucose via Activation of the Nrf2/HO-1 Signaling Pathway in Type 2 Diabetic Osteoporosis. ( Chen, B; Chen, C; Chen, P; Chen, W; Chi, W; He, Q; Li, M; Li, S; Pan, Z; Pang, X; Tu, H; Wang, F; Wang, H; Xiao, J; Yang, J; Yi, Y; Zeng, J, 2023) |
| "Metformin can prevent hyperglycaemia-induced osteoporosis and decrease the bone fracture rate, but the mechanism has not been fully elucidated." | 4.31 | Metformin promotes osteogenic differentiation and prevents hyperglycaemia-induced osteoporosis by suppressing PPARγ expression. ( Lian, H; Shen, X; Wang, S; Xie, Y; Yan, S; Zheng, L, 2023) |
| "To investigate the causal relationship between metformin use and osteoporosis and different subtypes of osteoporosis using a 2-sample Mendelian randomization method." | 4.31 | Causal association of metformin and osteoporosis: A 2-sample Mendelian randomization study. ( Chen, PB; Deng, GH; Ju, LL; Wei, YK, 2023) |
| "Metformin treatment was associated with a higher T-score and a lower odds ratio of osteopenia and osteoporosis, especially in the female population, independent of age, BMI, and eGFR." | 4.12 | Metformin treatment is associated with an increase in bone mineral density in type 2 diabetes mellitus patients in China: A retrospective single center study. ( He, H; Jiang, L; Lee, KO; Li, D; Liu, Q; Ma, J; Sun, J, 2022) |
| "Linagliptin and its combination with metformin successfully ameliorated diabetic osteoporosis in HFD-fed mice possibly through modulation of BMP-2 and sclerostin." | 4.12 | Linagliptin in Combination With Metformin Ameliorates Diabetic Osteoporosis Through Modulating BMP-2 and Sclerostin in the High-Fat Diet Fed C57BL/6 Mice. ( Nirwan, N; Vohora, D, 2022) |
| "To investigate the metformin effect on the risk of osteoporosis (OS) and/or vertebral fracture (VF)." | 4.02 | Metformin use is associated with a lower risk of osteoporosis/vertebral fracture in Taiwanese patients with type 2 diabetes mellitus. ( Tseng, CH, 2021) |
| "Metformin may decrease cell senescence, including bone; hence we aimed at evaluating the association between metformin use and osteoporosis." | 3.96 | Metformin use is associated with a lower risk of osteoporosis in adult women independent of type 2 diabetes mellitus and obesity. REDLINC IX study. ( Aedo, S; Arriola-Montenegro, J; Arteaga, E; Belardo, A; Blümel, JE; Chedraui, P; Fighera, TM; López, M; Martino, M; Miranda, C; Miranda, O; Mostajo, D; Ñañez, M; Ojeda, E; Pilnik, S; Rojas, J; Salinas, C; Sosa, L; Spritzer, PM; Tserotas, K; Vallejo, MS, 2020) |
| "Osteoporosis is a common bone disorder with adverse effects on oral osseointegration, and the effects of metformin on bone metabolism have received increasing attention." | 3.96 | Metformin promotes the osseointegration of titanium implants under osteoporotic conditions by regulating BMSCs autophagy, and osteogenic differentiation. ( Du, S; Jiang, H; Lin, J; Shen, X; Xu, R, 2020) |
| "Metformin (Met), an anti-diabetes drug, has also shown therapeutic effects for ovariectomy-induced (OVX) osteoporosis." | 3.91 | Metformin Alleviates the Bone Loss Induced by Ketogenic Diet: An In Vivo Study in Mice. ( Ding, J; Huang, Z; Kong, G; Li, R; Lin, J; Liu, J; Liu, Q; Liu, Y; Wu, X; Xu, X; Yang, Z; Zhu, Q, 2019) |
| "This study evaluated the preventative effects of metformin (Met) on glucocorticoid (GC)-induced osteoporosis in a rat model, compared with alendronate (Aln)." | 3.91 | Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats. ( Li, Q; Li, Y; Meng, Y; Shi, D; Zhang, H; Zhao, J; Zuo, L, 2019) |
| "In this review the problem of how to treat osteoporosis in patient with diabetes is also discussed." | 2.61 | Effect of antidiabetic treatment on bone. ( Jackuliak, P; Kužma, M; Payer, J, 2019) |
| " We also assessed the effect and mechanism of treatment with Met combined with TFRD on ovariectomy (OVX)-induced osteoporosis in rats." | 1.91 | The mechanism of metformin combined with total flavonoids of Rhizoma Drynariae on ovariectomy-induced osteoporotic rats. ( Chen, X; Jiang, N; Jin, H; Xu, H; Xu, W; Yang, K; Zhang, Z, 2023) |
| "Met may also treat diabetic osteoporosis through Wnt/β-catenin activation." | 1.72 | Metformin activates Wnt/β-catenin for the treatment of diabetic osteoporosis. ( Huang, X; Li, S; Lu, W; Xiong, L, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.45) | 18.2507 |
| 2000's | 1 (3.45) | 29.6817 |
| 2010's | 15 (51.72) | 24.3611 |
| 2020's | 12 (41.38) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, X | 1 |
| Liang, M | 1 |
| Sun, J | 1 |
| Liu, Q | 2 |
| He, H | 1 |
| Jiang, L | 1 |
| Lee, KO | 1 |
| Li, D | 1 |
| Ma, J | 1 |
| Huang, X | 1 |
| Li, S | 2 |
| Lu, W | 1 |
| Xiong, L | 1 |
| Nirwan, N | 1 |
| Vohora, D | 1 |
| Chen, B | 1 |
| He, Q | 1 |
| Yang, J | 1 |
| Pan, Z | 1 |
| Xiao, J | 1 |
| Chen, W | 1 |
| Chi, W | 1 |
| Li, M | 1 |
| Zeng, J | 1 |
| Chen, C | 1 |
| Wang, F | 1 |
| Pang, X | 1 |
| Yi, Y | 1 |
| Tu, H | 1 |
| Wang, H | 1 |
| Chen, P | 1 |
| Zheng, L | 1 |
| Shen, X | 2 |
| Xie, Y | 1 |
| Lian, H | 1 |
| Yan, S | 1 |
| Wang, S | 1 |
| Chen, RD | 1 |
| Yang, CW | 1 |
| Zhu, QR | 1 |
| Li, Y | 2 |
| Hu, HF | 1 |
| Wang, DC | 1 |
| Han, SJ | 1 |
| Jiang, N | 1 |
| Jin, H | 1 |
| Yang, K | 1 |
| Zhang, Z | 2 |
| Xu, W | 1 |
| Chen, X | 1 |
| Xu, H | 1 |
| Wei, YK | 1 |
| Chen, PB | 1 |
| Ju, LL | 1 |
| Deng, GH | 1 |
| Jackuliak, P | 1 |
| Kužma, M | 1 |
| Payer, J | 1 |
| Blümel, JE | 1 |
| Arteaga, E | 1 |
| Aedo, S | 1 |
| Arriola-Montenegro, J | 1 |
| López, M | 1 |
| Martino, M | 1 |
| Miranda, C | 1 |
| Miranda, O | 1 |
| Mostajo, D | 1 |
| Ñañez, M | 1 |
| Ojeda, E | 1 |
| Pilnik, S | 1 |
| Rojas, J | 1 |
| Salinas, C | 1 |
| Sosa, L | 1 |
| Spritzer, PM | 1 |
| Tserotas, K | 1 |
| Vallejo, MS | 1 |
| Belardo, A | 1 |
| Fighera, TM | 1 |
| Chedraui, P | 1 |
| Lin, J | 2 |
| Xu, R | 1 |
| Jiang, H | 1 |
| Du, S | 1 |
| Tseng, CH | 1 |
| Lecka-Czernik, B | 1 |
| Rozas-Moreno, P | 1 |
| Reyes-García, R | 1 |
| Jódar-Gimeno, E | 1 |
| Varsavsky, M | 1 |
| Luque-Fernández, I | 1 |
| Cortés-Berdonces, M | 1 |
| Muñoz-Torres, M | 1 |
| Fixen, CW | 1 |
| Fixen, DR | 1 |
| Xu, X | 1 |
| Yang, Z | 1 |
| Liu, Y | 1 |
| Wu, X | 1 |
| Huang, Z | 2 |
| Liu, J | 1 |
| Kong, G | 1 |
| Ding, J | 1 |
| Li, R | 1 |
| Zhu, Q | 1 |
| Bahrambeigi, S | 1 |
| Yousefi, B | 1 |
| Rahimi, M | 1 |
| Shafiei-Irannejad, V | 1 |
| Zhao, J | 1 |
| Zhang, H | 1 |
| Shi, D | 1 |
| Li, Q | 1 |
| Meng, Y | 1 |
| Zuo, L | 1 |
| Schlechte, JA | 1 |
| Antonopoulou, M | 1 |
| Bahtiyar, G | 1 |
| Banerji, MA | 1 |
| Sacerdote, AS | 1 |
| Jeyabalan, J | 1 |
| Viollet, B | 1 |
| Smitham, P | 1 |
| Ellis, SA | 1 |
| Zaman, G | 1 |
| Bardin, C | 1 |
| Goodship, A | 1 |
| Roux, JP | 1 |
| Pierre, M | 1 |
| Chenu, C | 1 |
| Ham, AC | 1 |
| Enneman, AW | 1 |
| van Dijk, SC | 1 |
| Oliai Araghi, S | 1 |
| Swart, KM | 1 |
| Sohl, E | 1 |
| van Wijngaarden, JP | 1 |
| van der Zwaluw, NL | 1 |
| Brouwer-Brolsma, EM | 1 |
| Dhonukshe-Rutten, RA | 1 |
| van Schoor, NM | 1 |
| van der Cammen, TJ | 1 |
| Zillikens, MC | 1 |
| de Jonge, R | 1 |
| Lips, P | 1 |
| de Groot, LC | 1 |
| van Meurs, JB | 1 |
| Uitterlinden, AG | 1 |
| Witkamp, RF | 1 |
| Stricker, BH | 1 |
| van der Velde, N | 1 |
| Bloomgarden, ZT | 1 |
| Kanazawa, I | 1 |
| Yamaguchi, T | 1 |
| Yano, S | 1 |
| Yamamoto, M | 1 |
| Yamauchi, M | 1 |
| Kurioka, S | 1 |
| Sugimoto, T | 1 |
| Mai, QG | 1 |
| Zhang, ZM | 1 |
| Xu, S | 1 |
| Lu, M | 1 |
| Zhou, RP | 1 |
| Zhao, L | 1 |
| Jia, CH | 1 |
| Wen, ZH | 1 |
| Jin, DD | 1 |
| Bai, XC | 1 |
| Ljunggren, Ö | 1 |
| Bolinder, J | 1 |
| Johansson, L | 1 |
| Wilding, J | 1 |
| Langkilde, AM | 1 |
| Sjöström, CD | 1 |
| Sugg, J | 1 |
| Parikh, S | 1 |
| Montagnani, A | 1 |
| Gonnelli, S | 1 |
| Watts, NB | 1 |
| Blevins, LS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Simvastatin on Bone Density in Postmenopausal Women With Type 2 Diabetes: a Double-blind, Randomized Active-comparator (Ezetimibe) Controlled Clinical Trial[NCT05613400] | Phase 4 | 240 participants (Anticipated) | Interventional | 2022-04-13 | Enrolling by invitation | ||
| A 24-week,Multi-centre,Int.,Double-blind,Rand.,Parallel-group,Plac.-Controlled,Phase III Study With a 78-week Ext.Per. to Evaluate the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type2 Diabetes Mellitus Who Have I[NCT00855166] | Phase 3 | 182 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 24 weeks of double-blind treatment on total body fat mass measured by dual energy X-ray absorptiometry. (NCT00855166)
Timeframe: Baseline to Week 24
| Intervention | kg (Least Squares Mean) |
|---|---|
| Placebo Plus Metformin | -0.74 |
| Dapagliflozin Plus Metformin | -2.22 |
To evaluate the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin on total body weight after 24 weeks of oral administration of double-blind treatment. (NCT00855166)
Timeframe: Baseline to Week 24
| Intervention | kg (Least Squares Mean) |
|---|---|
| Placebo Plus Metformin | -0.88 |
| Dapagliflozin Plus Metformin | -2.96 |
To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 24 weeks of double-blind treatment on waist circumference. (NCT00855166)
Timeframe: Baseline to Week 24
| Intervention | cm (Least Squares Mean) |
|---|---|
| Placebo Plus Metformin | -0.99 |
| Dapagliflozin Plus Metformin | -2.51 |
To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 102 weeks of double-blind treatment on Bone Mineral Density at femoral neck as measured by Dual Energy X-ray Absorptiometry. (NCT00855166)
Timeframe: Baseline to Week 102
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Placebo Plus Metformin | 0.09 |
| Dapagliflozin Plus Metformin | -0.85 |
To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 102 weeks of double-blind treatment on Bone Mineral Density at lumbar spine (L1-4) as measured by Dual Energy X-ray Absorptiometry. (NCT00855166)
Timeframe: Baseline to Week 102
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Placebo Plus Metformin | 0.47 |
| Dapagliflozin Plus Metformin | 0.69 |
To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 102 weeks of double-blind treatment on Bone Mineral Density at total hip as measured by Dual Energy X-ray Absorptiometry. (NCT00855166)
Timeframe: Baseline to Week 102
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Placebo Plus Metformin | -0.37 |
| Dapagliflozin Plus Metformin | -0.82 |
To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 24 weeks of double-blind treatment on body weight decrease ≥5%. Least Squares Mean represents the percent of participants adjusted for body weight baseline value. (NCT00855166)
Timeframe: Baseline to Week 24
| Intervention | Percentage of participants (Least Squares Mean) |
|---|---|
| Placebo Plus Metformin | 4.3 |
| Dapagliflozin Plus Metformin | 30.6 |
7 reviews available for metformin and Osteoporosis
| Article | Year |
|---|---|
Comparison of the Effects of Metformin and Thiazolidinediones on Bone Metabolism: A Systematic Review and Meta-Analysis.
Topics: Bone Density; Diabetes Mellitus, Type 2; Humans; Metformin; Osteoporosis; Thiazolidinediones | 2023 |
Effect of antidiabetic treatment on bone.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Diabetes Mellitus, Type 2; Humans; Hypogl | 2019 |
Diabetes, bone and glucose-lowering agents: basic biology.
Topics: Animals; Biomarkers; Blood Flow Velocity; Blood Glucose; Bone and Bones; Bone Density; Diabetes Mell | 2017 |
Managing and maintaining bone mineral density in diabetes patients with pharmacotherapy.
Topics: Bone Density; Canagliflozin; Diabetes Complications; Diabetes Mellitus; Fractures, Bone; Humans; Hyp | 2017 |
Metformin; an old antidiabetic drug with new potentials in bone disorders.
Topics: AMP-Activated Protein Kinases; Animals; Bone Diseases; Diabetes Mellitus, Type 2; Fractures, Bone; H | 2019 |
Diabetes and bone health.
Topics: Bone and Bones; Bone Density; Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agents | 2013 |
Antidiabetic therapy effects on bone metabolism and fracture risk.
Topics: Aging; Animals; Bone Density; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Pepti | 2013 |
2 trials available for metformin and Osteoporosis
| Article | Year |
|---|---|
Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus.
Topics: Aged; Atherosclerosis; Biomarkers; Blood Glucose; Body Weight; Bone Density; Collagen; Diabetes Mell | 2010 |
Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.
Topics: Absorptiometry, Photon; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Dens | 2012 |
20 other studies available for metformin and Osteoporosis
| Article | Year |
|---|---|
Metformin alleviates dexamethasone-induced apoptosis by regulating autophagy via AMPK/mTOR/p70S6K in osteoblasts.
Topics: AMP-Activated Protein Kinases; Apoptosis; Autophagy; Dexamethasone; Humans; Metformin; Osteoblasts; | 2022 |
Metformin treatment is associated with an increase in bone mineral density in type 2 diabetes mellitus patients in China: A retrospective single center study.
Topics: Absorptiometry, Photon; Bone Density; Bone Diseases, Metabolic; China; Diabetes Mellitus, Type 2; Fe | 2022 |
Metformin activates Wnt/β-catenin for the treatment of diabetic osteoporosis.
Topics: Animals; beta Catenin; Core Binding Factor Alpha 1 Subunit; Diabetes Mellitus; Metformin; Mice; Oste | 2022 |
Linagliptin in Combination With Metformin Ameliorates Diabetic Osteoporosis Through Modulating BMP-2 and Sclerostin in the High-Fat Diet Fed C57BL/6 Mice.
Topics: Animals; Biomarkers; Body Weight; Calcium; Cytokines; Diabetes Mellitus, Experimental; Diet, High-Fa | 2022 |
Metformin suppresses Oxidative Stress induced by High Glucose via Activation of the Nrf2/HO-1 Signaling Pathway in Type 2 Diabetic Osteoporosis.
Topics: Animals; Diabetes Mellitus, Type 2; Glucose; Heme Oxygenase-1; Metformin; Mice; NF-E2-Related Factor | 2023 |
Metformin promotes osteogenic differentiation and prevents hyperglycaemia-induced osteoporosis by suppressing PPARγ expression.
Topics: AMP-Activated Protein Kinases; Animals; Cell Differentiation; Diabetes Mellitus, Experimental; Hyper | 2023 |
The mechanism of metformin combined with total flavonoids of Rhizoma Drynariae on ovariectomy-induced osteoporotic rats.
Topics: Animals; Female; Humans; Metformin; Osteoclasts; Osteoporosis; Ovariectomy; RANK Ligand; Rats; Rats, | 2023 |
Causal association of metformin and osteoporosis: A 2-sample Mendelian randomization study.
Topics: Female; Fractures, Spontaneous; Genome-Wide Association Study; Humans; Mendelian Randomization Analy | 2023 |
Metformin use is associated with a lower risk of osteoporosis in adult women independent of type 2 diabetes mellitus and obesity. REDLINC IX study.
Topics: Aged; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Latin | 2020 |
Metformin promotes the osseointegration of titanium implants under osteoporotic conditions by regulating BMSCs autophagy, and osteogenic differentiation.
Topics: Animals; Autophagy; Cell Differentiation; Cellular Senescence; Female; Mesenchymal Stem Cells; Metfo | 2020 |
Metformin use is associated with a lower risk of osteoporosis/vertebral fracture in Taiwanese patients with type 2 diabetes mellitus.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Incidence; | 2021 |
Recommendations on the effect of antidiabetic drugs in bone.
Topics: Aged; Bone Remodeling; Bone Resorption; Contraindications, Drug; Diabetes Mellitus, Type 2; Dipeptid | 2017 |
Metformin Alleviates the Bone Loss Induced by Ketogenic Diet: An In Vivo Study in Mice.
Topics: Animals; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Cancellous Bone; Cortical Bone; Die | 2019 |
Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats.
Topics: Alendronate; Animals; Blood Glucose; Body Weight; Bone Density; Female; Femur; Glucocorticoids; Lipi | 2019 |
Update in endocrinology: evidence published in 2012.
Topics: Biliopancreatic Diversion; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; | 2013 |
The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing.
Topics: AMP-Activated Protein Kinases; Animals; Bone Density; Bone Remodeling; Bony Callus; Enzyme Activatio | 2013 |
Associations between medication use and homocysteine levels in an older population, and potential mediation by vitamin B12 and folate: data from the B-PROOF Study.
Topics: Aged; Diuretics; Female; Folic Acid; Health Services for the Aged; Homocysteine; Humans; Male; Metfo | 2014 |
Bone disease, gestational diabetes mellitus, and health care.
Topics: Bone Density; Bone Diseases; Collagen; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Fra | 2009 |
Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats.
Topics: Animals; Blotting, Western; Cell Differentiation; Cells, Cultured; Enzyme-Linked Immunosorbent Assay | 2011 |
Endocrinology.
Topics: Bone Resorption; Endocrinology; Graves Disease; Humans; Hyperparathyroidism; Hypoglycemic Agents; Me | 1996 |